KMDA - Kamada Ltd.
| Previous Close | 5.04 |
| Open | 5.09 |
| Bid | 5.10 x 3200 |
| Ask | 5.27 x 800 |
| Day's Range | 5.09 - 5.29 |
| 52 Week Range | 4.63 - 6.70 |
| Volume | 33,035 |
| Avg. Volume | 26,998 |
| Market Cap | 214.275M |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | 8.13 |
| EPS (TTM) | 0.65 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
- GlobeNewswire
Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference
REHOVOT, Israel, Sept. 24, 2019 -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive.
- GlobeNewswire
Kamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current.
- GlobeNewswire
Kamada Reports Discussions with Takeda Regarding a Potential Extension of the Period for the Transition of GLASSIA Manufacturing to Takeda
TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda to extend the period prior to transitioning the manufacture of GLASSIA, Kamada’s proprietary product for the treatment of Alpha-1 Antitrypsin Deficiency, to Takeda. Kamada will provide additional information regarding the discussions, if appropriate, at a later date. As background, Kamada has supplied GLASSIA to Takeda, or its predecessors, since 2010. The GLASSIA supply agreement with Takeda currently extends through the end of 2020, followed by an expected transition of GLASSIA manufacturing to Takeda. While the transition of GLASSIA manufacturing to Takeda after 2020 will result in a significant reduction of Kamada’s revenues, based on the current terms of the supply agreement, Kamada would be entitled to future royalty payments until 2040.
Motley FoolKamada Ltd. (KMDA) Q2 2019 Earnings Call Transcript
KMDA earnings call for the period ending June 30, 2019.
- Zacks
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
Kamada (KMDA) delivered earnings and revenue surprises of 6.67% and 4.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Kamada Reports Financial Results for Second Quarter and First Six Months of 2019
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-YearTotal Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase.
- GlobeNewswire
Kamada to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6
REHOVOT, Israel, July 31, 2019 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
- Zacks
Kamada (KMDA) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services
Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services
- Zacks
Look Beyond Earnings: 4 Stocks With Increasing Cash Flows
Cash is an indispensable factor for any company. It gives strength and vitality to a company and is the key to its existence, development and success.
- Zacks
Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX
Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX
- Zacks
Tap These 6 Stocks That Flaunt Impressive Net Profit Margin
Let's consider six stocks with a remarkable net profit margin to build a successful portfolio.
- Benzinga
Cannabics Pharmaceuticals Gets New Directors
Cannabics Pharmaceuticals Inc (OTC: CNBX), a company focused on personalizing cannabinoid medicine, especially in relation to cancer and its side effects, this week announced the appointment of two new members of their board of directors: Dr. Estery Giloz-Ran and Eran Ballan. Giloz-Ran is a certified public accountant and holds a PhD in tax, accounting and finance from Ben-Gurion University in Israel.
Motley FoolKamada Ltd. (KMDA) Q1 2019 Earnings Call Transcript
KMDA earnings call for the period ending March 31, 2019.
- Zacks
Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Kamada: 1Q Earnings Snapshot
The Rehovot, Israel-based company said it had net income of 12 cents per share. Earnings, adjusted for stock option expense, came to 13 cents per share. The biopharmaceutical posted revenue of $26.8 million ...
- GlobeNewswire
Kamada Reports Financial Results for First Quarter of 2019
Total Revenues for Q1 2019 were $26.8 Million, up 54% over Q1 2018Q1 2019 Proprietary Products Revenues up 67% Year-over-Year Gross Profit for Q1 2019 Grew 59%.
- Zacks
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.
- Benzinga
A Preview Of Kamada's Q1 Earnings
Kamada Ltd. (NASDAQ: KMDA ) releases its next round of earnings this Tuesday, May 14. Here's Benzinga's essential guide to Kamada's first-quarter earnings report. Earnings and Revenue Analysts covering ...
- Zacks
Kamada (KMDA) Stock Moves -1.05%: What You Should Know
Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.
- GlobeNewswire
Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
REHOVOT, Israel, May 07, 2019 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
- Zacks
Kamada (KMDA) Gains As Market Dips: What You Should Know
Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.
- Zacks
Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?
Is (KMDA) Outperforming Other Medical Stocks This Year?
